TrialBreast cancer research and treatment2015

Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.

Judith-Anne W Chapman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.